#117945
#117946
Re: Farmas USA
Justo miraba eso! olemos la sangre o las rosas jajajaja
Salto por que la VI se ha disparado
Salto por que la VI se ha disparado
Solo se que no se nada.
#117947
Re: Farmas USA
Se sabe por qué?
Si te sientas en la mesa y no descubres al "primo" es que lo eres tú.
#117948
Re: Farmas USA
In this, probably the expected FDA nod for a CV benefit claim for Vascepa (icosapent ethyl). The agency's action date is December 28.
AMRN
AMRN
Solo se que no se nada.
#117950
Re: Farmas USA
No se sabe xo he leído que se ha detectado actividad call alta hoy.
Puede ser decisión del label x parte de la FDA adelantada w se esperaba xa 28 pero siendo estas fechas se hayan adelantado ...
Puede ser decisión del label x parte de la FDA adelantada w se esperaba xa 28 pero siendo estas fechas se hayan adelantado ...
#117951
Re: Farmas USA
Amarin up 7% after positive Ad Com vote on CV claim for Vascepa
Nov. 15, 2019 8:09 AM ET|About: Amarin Corporation plc (AMRN)|By: Douglas W. House, SA News Editor
Amarin (NASDAQ:AMRN) is up 7% premarket on robust volume after yesterday's positive vote from an FDA advisory committee backing a CV benefit claim for Vascepa (icosapent ethyl).
https://seekingalpha.com/news/3519725-amarin-up-7-after-positive-ad-com-vote-on-cv-claim-for-vascep
-----------
-----------
Amarin's Vascepa to become 'blockbuster,' analyst says in maintaining Buy
In a "conservative base case" where the drug is approved for secondary prevention along with additional patient qualifications, Vascepa could achieve sales "north of $2B a year" by 2025, Weinstein says in maintaining his Buy rating and $23 price target on the shares.
https://seekingalpha.com/news/3521887-amarins-vascepa-to-become-blockbuster-analyst-says-in-maintaining-buy
--------------
Amarin shares halted pending news
Dec. 13, 2019 1:10 PM ET|About: Amarin Corporation plc (AMRN)|By: Douglas W. House, SA News Editor
Nasdaq has suspended trading in Amarin (AMRN +4.9%) pending the release of news. In this, probably the expected FDA nod for a CV benefit claim for Vascepa (icosapent ethyl). The agency's action date is December 28
.https://seekingalpha.com/news/3526234-amarin-shares-halted-pending-news
.https://seekingalpha.com/news/3526234-amarin-shares-halted-pending-news
#117952
Re: Farmas USA
Otras de que replican a AMRN
Acasti Pharma Inc. (ACST) Market Cap | 149.32M
2.025+0.275 (+15.7143%)
As of 2:35PM EST. Market open.
------------
Matinas BioPharma Holdings, Inc. (MTNB
1.8201+0.2401 (+15.1962%) Market Cap | 247.89M
As of 2:37PM EST. Market open.
Acasti Pharma Inc. (ACST) Market Cap | 149.32M
2.025+0.275 (+15.7143%)
As of 2:35PM EST. Market open.
------------
Matinas BioPharma Holdings, Inc. (MTNB
1.8201+0.2401 (+15.1962%) Market Cap | 247.89M
As of 2:37PM EST. Market open.
--